Protagonist Therapeutics Reports $56M Q1 Revenue, Swings to Profit on ICOTYDE Milestone and Takeda Payment
summarizeSummary
Protagonist Therapeutics reported a significant Q1 financial turnaround, with revenue doubling to $56.37 million and the company swinging to a net income of $3.78 million from a loss in the prior year. This strong performance was primarily driven by a $50 million milestone payment from Johnson & Johnson following FDA approval of ICOTYDE, as well as additional revenue from Takeda reimbursements, including a $200 million opt-out payment for rusfertide. This marks a material improvement from the $130.1 million net loss reported for fiscal year 2025 and was not previously disclosed in the recent timeline. The substantial milestone payments and return to profitability are highly positive indicators for the company's financial health and product pipeline. Investors will now closely watch for the anticipated FDA decision for rusfertide in Q3 2026 under Priority Review, which could serve as another significant catalyst, and the company's extended cash runway through at least 2028.
At the time of this announcement, PTGX was trading at $99.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $41.29 to $107.84. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.